6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 17 Oct 2023
- Reporting date
- 17 Oct 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
GSK plc reports
- Company location
- London
GSK plc has filed 6,805 SEC EDGAR filings since 12 Jan 2001
SEC filing history
Showing 751-775 of 1,000 matching filings.
Per page
25
Current page
31
6-K
File 001-15170
JEMPERLI PLUS CHEMOTHERAPY POSITIVE CHMP OPINION
- Filing date
- 16 Oct 2023
- Reporting date
- 16 Oct 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 13 Oct 2023
- Reporting date
- 13 Oct 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Oct 2023
- Reporting date
- 12 Oct 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
ZANTAC (RANITIDINE) LITIGATION
- Filing date
- 11 Oct 2023
- Reporting date
- 11 Oct 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13D/A
AMENDMENT TO FORM SC 13D
- Filing date
- 10 Oct 2023
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK AND ZHIFEI ANNOUNCE VACCINE PARTNERSHIP
- Filing date
- 10 Oct 2023
- Reporting date
- 10 Oct 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
CURRENT REPORT
- Filing date
- 06 Oct 2023
- Reporting date
- 06 Oct 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK COMPLETES SALE OF SHARES IN HALEON PLC
- Filing date
- 06 Oct 2023
- Reporting date
- 06 Oct 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
25-NSE
File 001-15170
25-NSE filing
- Filing date
- 02 Oct 2023
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 02 Oct 2023
- Reporting date
- 02 Oct 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTORATE CHANGE
- Filing date
- 27 Sep 2023
- Reporting date
- 27 Sep 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK RSV VACCINE FOR OLDER ADULTS APPROVED IN JAPAN
- Filing date
- 25 Sep 2023
- Reporting date
- 25 Sep 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 21 Sep 2023
- Reporting date
- 21 Aug 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
APRETUDE FOR PREP RECEIVES EMA APPROVAL
- Filing date
- 19 Sep 2023
- Reporting date
- 19 Sep 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
FDA APPROVES OJJAARA (MOMELOTINIB)
- Filing date
- 18 Sep 2023
- Reporting date
- 18 Sep 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 13 Sep 2023
- Reporting date
- 13 Sep 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13D/A
AMENDMENT TO FORM SC 13D
- Filing date
- 11 Sep 2023
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 11 Sep 2023
- Reporting date
- 11 Sep 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
MOMELOTINIB FILING ACCEPTED IN JAPAN
- Filing date
- 11 Sep 2023
- Reporting date
- 11 Sep 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 06 Sep 2023
- Reporting date
- 06 Sep 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 01 Sep 2023
- Reporting date
- 01 Sep 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK'S NUCALA CRSWNP SUBMISSION ACCEPTED IN JAPAN
- Filing date
- 01 Sep 2023
- Reporting date
- 01 Sep 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
HOLDING(S) IN COMPANY
- Filing date
- 31 Aug 2023
- Reporting date
- 31 Aug 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
HOLDING(S) IN COMPANY
- Filing date
- 31 Aug 2023
- Reporting date
- 31 Aug 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing